Rahul Saraogi is the classic “Ben Graham” sort of investor, looking for top-quality companies which have “deep value” and are quoting at bargain-basement prices. His latest stock pick has all these attributes. Despite an adverse business environment, it has outperformed all of its peers
The perils of a concentrated portfolio are exemplified by the steep losses suffered by Tiger Ratan Capital Fund. The downturn in just two stocks has sent the AUM plunging a whopping 33% in just three months
If you have ever wondered how savvy investors always steal a march over novice investors, it is because of their incredible ability to look beyond the present and foresee future events. Vijay Kedia has given us a glimpse of his brilliant investing mind by analyzing what NAMO’s electoral debacle means and how we can profit from it
A well known film actor with Bollywood and Hollywood blockbuster films to his credit has turned into a stock picker. His debut stock recommendation has given 100% gains in just 4 months. He promises more multibagger gains from the stock
Kotak Securities has issued a report in which it has recommended investment in 11 top-quality large-cap and mid-cap stocks on the occasion of Diwali 2015
A stock aptly described by Brahmal Vasudevan and Anand Narayan as “an exceptional co experiencing a phenomenal growth rate” has given magnificent gains in the short-term and looks good for more gains in the future
A punter who devised a devious plan to send the stock price surging or plunging based on bogus tweets has been busted and faces 25 years in jail. Sadly for him, while he caused a market loss of Rs. 8 crore, his gains from the fraud was only Rs. 6,000
Though old-school investors of the proven caliber of Rakesh Jhunjhunwala, Prem Watsa, Samir Arora and others offered sensible advice, new-age investors behaved like drunken sailors and poured billions of dollars into dubious e-com ventures run by college dropouts. Now, these ventures are proving to be bottomless pits and the investors are wailing over their losses
Amar Ambani of IIFL has evaluated the Q2FY16 performance of several stocks and given buy/ sell recommendations with price targets
After Bill Ackman, Ruane Cunniff, another large shareholder of Valeant Pharma, has rushed to the defense of Valeant Pharma. It complained of experiencing “extraordinary level of pain” at the steep plunge of Valeant’s stock price but gave a clean chit to the beleaguered company and its CEO
Recent Comments